One Global Service Provider Limited ONEGLOBAL NSEPHARMA
Company Overview
One Global Service Provider Limited engages in the provision of healthcare services worldwide. The company offers diagnostic services, including anemia, antenatal, diabetes, diabetes monitoring, hypertension, kidney, and lipid profiles, as well as liver function tests; and healthcare services, such as end-to-end solutions in industrial occupational check-ups, population screening for non-communicable diseases, disease surveillance programs, electronic medical records and health registry, health analytics for predictive and preventive actions, and wellness programs for lifestyle diseases. It also provides laboratory services, such as biochemistry, microbiology, hematology and coagulation, histopathology and cytopathology, clinical pathology, molecular diagnostics, and serology. In addition, the company offers healthcare products, such as medical devices, equipment, medical consumables, and reagents through an online platform; and healthcare solutions comprising home-based health screening, public health data analytics, and home-based remote care services. Further, it involves in consultancy and development, requirements, designs, develops, tests, integrates, deploys, and maintains software/IT products; and purchases, sells, distributes licenses, resells, imports, exports IT and/or software products. The company was formerly known as Overseas Synthetics Limited. One Global Service Provider Limited was incorporated in 1992 and is based in Mumbai, India.
Why Investors Should Care
Generates a return on equity of 49.2%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 65.3%.
Net profit has compounded at 269.4% per year over the last five years.
Revenue has grown at a 201.8% CAGR over the past five years.
Trades at a P/E of 9.4, below the sector median of 35.9.
Operating margin of 18.5% supports profitability.
Recent Developments
- Mar 2026 Revenue of ₹498.18 Cr (+238.8% YoY); net profit ₹69.50 Cr.
- Trailing 12 Months Year-on-year growth — revenue +17.0%, earnings +45.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 201.8%, profit CAGR 269.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 201.84% |
| 1 Year: | 17.00% |
Compounded Profit Growth
| 5 Years: | 269.37% |
| 1 Year: | 45.80% |
Stock Price Performance
| 1 Year: | -33.29% |
| 6 Months: | - |
| 3 Months: | - |
| 1 Month: | -33.51% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- RSI (14)24.20 · Oversold
P/E of 9.44 is below the sector median of 35.90 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 49.2%.
- Healthy ROCE of 65.3%.
- Compounding revenue at 201.8% over 5 years.
- Profit CAGR of 269.4% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 38.9% below its 52-week high.
- RSI at 24 suggests oversold conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ONEGLOBAL One Global Service Provider Limited NSEPHARMA | 357.60 | 9.44 | ₹724.11 Cr | 0.19% | 65.26% | 49.21% | 201.84% | 269.37% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,758.00 | 34.88 | ₹4.22 L Cr | 0.91% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 9,162.00 | 83.32 | ₹2.43 L Cr | 0.32% | 18.96% | 15.32% | 10.98% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,615.30 | 73.73 | ₹1.76 L Cr | 0.81% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,135.00 | 25.30 | ₹1.13 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 6 | LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA | 634.25 | 165.17 | ₹1.10 L Cr | 0.00% | 7.21% | 5.65% | 35.38% | 66.99% |
| 7 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 7,604.50 | 52.35 | ₹1.09 L Cr | 0.25% | 19.20% | 20.48% | 14.85% | 33.34% |
| 8 | LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA | 2,002.50 | 98.99 | ₹1.08 L Cr | 0.12% | 19.53% | 16.77% | 3.77% | 4.00% |
| 9 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,330.90 | 31.92 | ₹1.08 L Cr | 0.99% | 14.86% | 11.27% | 7.23% | 11.45% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 55.46 Cr | 87.83 Cr | 134.98 Cr | 141.27 Cr | 133.81 Cr |
| Cost of Revenue | 34.83 Cr | 70.24 Cr | 105.20 Cr | 110.13 Cr | 103.55 Cr |
| Gross Profit | 20.63 Cr | 17.59 Cr | 29.79 Cr | 31.14 Cr | 30.26 Cr |
| Operating Expenses | 6.30 Cr | 4.52 Cr | 3.85 Cr | 2.23 Cr | 6.35 Cr |
| Operating Income | 14.33 Cr | 13.07 Cr | 25.94 Cr | 28.91 Cr | 23.91 Cr |
| EBITDA | 14.90 Cr | 13.27 Cr | 26.57 Cr | 28.98 Cr | 24.69 Cr |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Pretax Income | 14.61 Cr | 13.09 Cr | 26.39 Cr | 28.91 Cr | 24.34 Cr |
| Tax Provision | 3.61 Cr | 3.28 Cr | 6.60 Cr | 7.25 Cr | 6.15 Cr |
| Net Income | 11.00 Cr | 9.82 Cr | 19.79 Cr | 21.66 Cr | 18.19 Cr |
| Diluted EPS | - | - | - | - | - |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 18.12 Cr | 63.01 Cr | 147.04 Cr | 498.18 Cr |
| Cost of Revenue | - | 13.87 Cr | 48.64 Cr | 93.93 Cr | 389.12 Cr |
| Gross Profit | - | 4.25 Cr | 14.37 Cr | 53.11 Cr | 109.06 Cr |
| Operating Expenses | - | 2.89 Cr | 4.87 Cr | 29.45 Cr | 16.88 Cr |
| Operating Income | - | 1.36 Cr | 9.49 Cr | 23.66 Cr | 92.18 Cr |
| EBITDA | - | 1.65 Cr | 9.73 Cr | 25.95 Cr | 93.49 Cr |
| Interest Expense | - | 52,000 | 0 | 0 | 0 |
| Pretax Income | - | 1.36 Cr | 9.50 Cr | 24.79 Cr | 92.81 Cr |
| Tax Provision | - | -2.33 L | 2.39 Cr | 6.33 Cr | 23.31 Cr |
| Net Income | - | 1.38 Cr | 7.11 Cr | 18.47 Cr | 69.50 Cr |
| Diluted EPS | - | - | - | - | - |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 12.83 Cr | 31.81 Cr | 106.33 Cr | 255.31 Cr |
| Current Assets | - | 8.98 Cr | 28.17 Cr | 85.04 Cr | 234.40 Cr |
| Cash & Equivalents | - | 2.76 L | 1.23 Cr | 27.15 Cr | 15.67 Cr |
| Inventory | - | 0 | 0 | 0 | 76,000 |
| Receivables | - | 8.14 Cr | 26.18 Cr | 54.06 Cr | 216.58 Cr |
| Total Liabilities | - | 5.53 Cr | 17.41 Cr | 34.60 Cr | 114.08 Cr |
| Current Liabilities | - | 5.19 Cr | 17.07 Cr | 34.26 Cr | 114.05 Cr |
| Long Term Debt | - | 33.93 L | 33.93 L | 33.93 L | 3.12 L |
| Total Debt | - | 33.93 L | 33.93 L | 33.93 L | 3.12 L |
| Total Equity | - | 7.29 Cr | 14.40 Cr | 71.72 Cr | 141.23 Cr |
| Shares Outstanding | - | 71.05 L | 71.05 L | 71.05 L | 1.95 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 13.92 L | 1.21 Cr | 14.45 Cr | 2.76 Cr |
| Investing Cash Flow | - | -16.12 L | -1.14 L | -11.07 L | -30.12 L |
| Financing Cash Flow | - | 0 | 0 | -71.05 L | -30.82 L |
| Capital Expenditure | -54.00 L | -16.12 L | -1.14 L | -11.07 L | - |
| Free Cash Flow | - | -2.20 L | 1.20 Cr | 14.45 Cr | 2.76 Cr |
| Net Change in Cash | - | -2.20 L | 1.20 Cr | 13.63 Cr | 2.15 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 23.4% | 22.8% | 36.1% | 21.9% |
| Operating Margin % | - | 7.5% | 15.1% | 16.1% | 18.5% |
| Net Margin % | - | 7.6% | 11.3% | 12.6% | 14.0% |
| ROE % | - | 18.9% | 49.4% | 25.7% | 49.2% |
| ROCE % | - | 17.9% | 64.4% | 32.8% | 65.3% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ONEGLOBAL
Helium One Global Limited (HLOGF) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiU0FVX3lxTE96M29naW9DUWVVTDRNRlFuQ1hkeGdtTHQ2WnJzT3dSQ084N1JBWVE4TlhIMUxoalp6MENrVlM0Mm5lVG5qNWdJd0tKQjFnQm8wTFkw?oc=5" target="_blank">Helium One Global Limited (HLOGF) Stock Price, News, Qu…
ONEGLOBAL Stock Price and Chart — NSE:ONEGLOBAL - TradingView
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9qQm0ySExEanB6Q2ZKSzFvNktobDZyeGpiV2UtV09jcTlkRmdvaTBsZ21YVE1QSFBZQXB0ZTNlR0RZWnVmRUZSRFRpX3lsSk9GQy1DWWUtVlJ2WGhBTmQw?oc=5" target="_blank">ONEGLOBAL Stock Price and Chart — NSE:O…
One Global buys 51% of Matrix Labs diagnostics arms in Rs 39.54 crore stock deal - Dealroom
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxQVGQ1S3RlQzZ3QjF2a2ZKUnZnNDdIVFpnRHNJS3Vmc0w1eFR6ZHo3YnVmSi1ndHBmLWl5UjRMY3ppWWl6UGVXOVFrc05HNV9fN2ZCbmtyTGNYamdaOTQwZlBwLVZ0c29BX05wT0dQemNNTUU2MW94M0xjLWtoY1lEZUR2ZXlJUXNjTWU3NV…
U.S. Exceptionalism May Have Peaked, According to Fidelity. Here's One Global ETF Worth Looking At. - The Motley Fool
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxOdkpqMXEwUHhHQ0JyOVhDYkdZc1ZlRTFRRzZHdXBIWm9jckZPNnczOXRxdDdZVVl5emZ6bW0yZFIyZUp4MTNjMlRvcGhiQUIxWkJiZ05qelZKVmplZl9sUnY3VVVuVFRBdFY1U2NZbzhIMlY4eExvakxicndyVWtWUXF5dDRWdXZZaU81RG…
One Global Service Provider Share Price Today Slides 18.88% - Univest
<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxPa3RMc2k1ZHBRRDM1eml4M0N5QnpZaWtSNUZUb3g5R3FUX3FhdVJiOF9IYmlSb0JNWVJpUVFuWjVlZkxyTndfdEI4VFhuMFp0dV9yQncyUzdZcU51U1BVSnViZkxkdGVicVZnTVZPeVRTME0yQjdHYTFrcWUwUkFIR2pSRzJpRFdQaUdILQ…
HELIUM ONE GLOBAL LTD (HE1) Equity Price and Quote - London Stock Exchange
<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxOMU9FR1c3LTlrWFR6UmhJUHNzaVcwcDFjd2VESlIzQVg2dmZ1aGpPZjFYYktZdWZoMGZ4REJieGFaVUFDTks2VUtUQTNqaWpEMEk5U0d4Y2RUR21kWUFBM2YzVWFHZndCMGk1bG5HNVdqREdiaXZ0OEZYRDBUajloeWppYw?oc=5" targe…
ONEGLOBAL — Frequently Asked Questions
What is the current share price of One Global Service Provider Limited (ONEGLOBAL)?
As of 2026-10-24 04:55 IST, One Global Service Provider Limited (ONEGLOBAL) trades at ₹357.60 on NSE. Its 52-week range is ₹357.60 to ₹585.00.
What is the market capitalisation of ONEGLOBAL?
One Global Service Provider Limited (ONEGLOBAL) has a market capitalisation of ₹724.11 Cr on NSE.
What is the P/E ratio of ONEGLOBAL?
ONEGLOBAL trades at a trailing price-to-earnings (P/E) ratio of 9.44. The industry average P/E is 35.90. Its price-to-book (P/B) ratio is 7.45.
Does ONEGLOBAL pay a dividend?
One Global Service Provider Limited (ONEGLOBAL) currently offers a dividend yield of 0.19%.
What is the return on equity (ROE) of ONEGLOBAL?
ONEGLOBAL has a return on equity (ROE) of 49.21%. Its return on capital employed (ROCE) is 65.26%.
Is ONEGLOBAL a good stock to buy?
This page provides a data-driven analysis of One Global Service Provider Limited (ONEGLOBAL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.